The mechanism and consequences of BRAF inhibitor resistance in melanoma
K Golub, W Bai, Z Zhang, H Xiao, R Sun, J Shen… - Genome Instability & …, 2023 - Springer
Abstract BRAF V600E is a constitutive BRAF (B-raf proto-oncogene, serine/threonine
kinase) mutation that accounts for more than 90% of BRAF mutations in melanoma …
kinase) mutation that accounts for more than 90% of BRAF mutations in melanoma …
DIRAS2 is a prognostic biomarker and linked with Immune infiltrates in Melanoma
W Xue, H Zhu, H Liu, H He - Frontiers in Oncology, 2022 - frontiersin.org
Background Skin cutaneous melanoma (SKCM) is a highly malignant skin tumor. DIRAS2 is
considered to be a tumor suppressor gene; however, its function in SKCM has not been …
considered to be a tumor suppressor gene; however, its function in SKCM has not been …
Cures with B-Raf inhibitors as single agents in metastatic B-Raf mutated melanoma: Curb your enthusiasm?
CA Dasanu - Journal of Oncology Pharmacy Practice, 2021 - journals.sagepub.com
Development of brain metastases during treatment with B-raf/MEK inhibitors for malignant
melanoma tends to be more frequent than during immune checkpoint inhibitor therapy. Long …
melanoma tends to be more frequent than during immune checkpoint inhibitor therapy. Long …